Speculative M&A Transaction Analysis, page-667

In my opinion, the Ideal outcome would be Zantrene sold for $80B-$100B Plus ongoing plus ongoing Royalties from Sales.
(I believe that the Royalties would be a critical part of any Sales deal, as it helps to bridge the gap between the initial Sales price, and the True expected Peak Annual sales - especially when the Zantrene potential seems Skyhigh right now)

Then RAC could focus on leveraging their knowledge and expertise in the area of FTO's and m6A molecules, and help pave the way forward in this ground breaking area - especially if it is setup to occur in Australia, and provide pathways for new research collaborations and help build Australia's Medical Research Industry.

And yes, a lot of people may say that it all seems unrealistic and pipedreams etc.
But if you don't aim for that high, and if you don't have faith, then how can you ever expect to achieve it?

Think Big, Aim High, Push Hard!